Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook

We recently published 10 Firms Dominating the Market; 5 at All-Time Highs. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the best-performing stocks on Friday.

Travere Therapeutics climbed to a fresh record high on Friday, as investors took heart from a stellar earnings performance and cues that the company would kick off the last month of the year on a strong note.

At intra-day trading, the stock soared to its highest price of $35.34 before trimming gains to end the day just up by 18.58 percent at $35.16 apiece.

Based on its financial statement on Thursday, Travere Therapeutics, Inc. (NASDAQ:TVTX) swung to a net income of $25.7 million in the third quarter of the year from a $54.8 million net loss in the same period last year.

Total revenues expanded by 162 percent to $164.8 million from $62.9 million year-on-year, helped by strong sales from its kidney disease treatment, Filspari.

According to Travere Therapeutics, Inc. (NASDAQ:TVTX), the drug incurred $90.9 million in sales in the US alone, representing a 155 percent growth year-on-year.

“We delivered outstanding commercial performance in the third quarter, reflecting the growing role of FILSPARI as a foundational therapy in IgAN. This success underscores the strength of our commercial execution and the expanding confidence in FILSPARI among physicians and patients,” Travere Therapeutics, Inc. (NASDAQ:TVTX) President and CEO Eric Dube said.

“We continue to be pleased with the progress of our sNDA review in FSGS and are actively preparing for a potential FDA approval early next year. We are also making meaningful progress toward restarting the pivotal HARMONY Study of pegtibatinase and have positioned the company to support long-term growth. We are entering the final months of 2025 in a position of strength as we remain focused on execution and on expanding our impact for people living with rare diseases,” he noted.

While we acknowledge the potential of TVTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.